AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01878747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Tailored Intervention for Perioperative Stress
Description: Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
Study NCT02884648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg by vein on Day 1 of every 21-day study cycle.
Study NCT02099838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Metformin
Description: taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
Study NCT00207714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
Study NCT00207714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
Study NCT00207714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
Study NCT00207714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
Study NCT00207714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
Study NCT05450497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: comparing sedative agents
Study NCT05450497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: comparing sedative agents
Study NCT05450497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and propofol
Description: comparing sedative agents
Study NCT02858856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang
Description: Herbal medicine which is a compound of 10 herbs.
Study NCT04953585 — intervention group
Intervention type: PROCEDURE
Intervention: radical gastrectomy
Description: According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy
Study NCT03764410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
Study NCT03764410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
Study NCT04158479 — intervention group
Intervention type: DEVICE
Intervention: ECMO
Description: ECMO for circulatory and/or respiratory support
Study NCT01634022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
Study NCT00624403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion (LMA ProSeal)
Description: Laryngeal mask insertion
Study NCT00624403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion (I-Gel)
Description: Laryngeal mask insertion
Study NCT00748813 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Vaccine, Formulation 2008-2009
Description: 1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
Study NCT02525328 — intervention group
Intervention type: OTHER
Intervention: blood or saliva specimen
Description: blood or saliva specimen is sampled for DNA extraction in CT family's members
Study NCT02099838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
Study NCT01227889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: 150 mg twice daily
Study NCT01227889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine (DTIC)
Description: Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
Study NCT01569516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine Succinate Tablets
Description: 1mg, tid
Study NCT01569516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine Succinate Tablets
Description: 1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
Study NCT01569516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine succinate Tablets
Description: 1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
Study NCT01569516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg, tid
Study NCT03571061 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: whole colon water immersion and sigmoid water immersion
Description: we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
Study NCT03571061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole colon water immersion and sigmoid water immersion
Description: we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
Study NCT03571061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: whole colon water immersion and sigmoid water immersion
Description: we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
Study NCT01230697 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: Sorafenib 800mg/die oral
Study NCT04480294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5091
Description: Single dose in group 1-5~Multiple doses in group 6-9
Study NCT04603937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection
Study NCT01308749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU.
Study NCT01308749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Nasal Spray
Study NCT04255160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (mylan or vivelle dot patch)
Description: Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
Study NCT04255160 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
Study NCT06349161 — intervention group
Intervention type: PROCEDURE
Intervention: One-trocar-assisted pyeloplasty
Description: Positioned in a full lateral decubitus posture. A 12mm incision was made below the 12th rib, followed by a muscle-sparing technique to access and open the Gerota's fascia. A 10mm balloon trocar was inserted, and CO2 was insufflated to a pressure of 12 mmHg at a flow rate of 3L. An operative scope with dual channels was introduced for retroperitoneal dissection, utilizing a peanut to expand the working space. The proximal ureter, UPJ, and renal pelvis were visualized, and the UPJ was mobilized and exteriorized under direct visualization to prevent torsion. Anderson-Hynes dismembered pyeloplasty was performed using a 6/0 PDS suture, with possible enlargement of the incision if necessary. A 4 French double J ureteral stent was inserted antegradely before completing the anastomosis, verified by methylene blue presence at the anastomotic site. A final retroperitoneoscopic assessment ensured proper alignment of the anastomosis, with closure of the incision site without drain placement.
Study NCT04603937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection
Study NCT04603937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT04603937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT01454882 — intervention group
Intervention type: BEHAVIORAL
Intervention: Effects of Clothing
Description: There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
Study NCT01454882 — intervention group
Intervention type: BEHAVIORAL
Intervention: Effects of Temperature
Description: There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
Study NCT01454882 — intervention group
Intervention type: BEHAVIORAL
Intervention: Low Physical Activity
Description: This will be a randomized study with two within subject conditions (high and low physical activity levels)
Study NCT01454882 — intervention group
Intervention type: BEHAVIORAL
Intervention: High Physical Activity
Description: This will be a randomized study with two within subject conditions (high and low physical activity levels)
Study NCT01454882 — intervention group
Intervention type: BEHAVIORAL
Intervention: Direct calorimetry and doubly labeled water
Description: TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
Study NCT04181996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Oral Product
Description: Patients will be randomized to receive either placebo or colchicine
Study NCT04181996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patents will be randomized to receive either placebo or colchicine
Study NCT03237611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
Study NCT03237611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 115 MG
Description: Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
Study NCT03916237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Medical Legal Partnership
Description: Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
Study NCT03237611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
Study NCT03237611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 MG
Description: Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
Study NCT01007591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 80190
Description: Applied once daily
Study NCT01007591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Applied once daily
Study NCT04440345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Administered by subcutaneous injection
Study NCT00448539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
Study NCT04440345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT03601832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-D navigated stereotactic radiosurgical ablation
Description: 4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
Study NCT04283383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Clinical Ultrasound Classroom (AECAP)
Description: A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out,
Study NCT02370602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets
Study NCT05743790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS2-control-RS4
Description: Group A: Treatment 1 = RS2 (Hi-Maize 260), Treatment 2 = Control (Amioca TF), Treatment 3 = RS4 (Versafibe 1490)
Study NCT05743790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS4-control-RS2
Description: Group B: Treatment 1 = RS4 (Versafibe 1490), Treatment 2 = Control (Amioca TF), Treatment 3 = RS2 (Hi-Maize 260)
Study NCT03168685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureSource Engage application
Description: Eligible patients who choose to participate in the study will be asked to wear an actigraphy device \[ActiGraph GT9X Link Actigraph Link\] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application.
Study NCT02370602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^11C]T-773
Description: \[\^11C\]T-773 IV solution
Study NCT05874869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: The drug will be administered once a day for three consecutive days for three months (March, April, and May)
Study NCT03210259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Duration - 58 weeks
Study NCT03210259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Description: Duration - 58 weeks
Study NCT03479385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Intervention
Description: Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
Study NCT03479385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Description: Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
Study NCT03310203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron
Description: Labelled iron
Study NCT01871987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: oral
Study NCT03016182 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
Study NCT03016182 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group witnout remote ischemic preconditioning
Study NCT01669720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
Study NCT02801591 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional ovarian stimulation proctol without rhGH
Study NCT04614974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.
Study NCT04614974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech Language Therapy
Description: Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
Study NCT04614974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech Language Therapy
Description: Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
Study NCT02071381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW330SR 45mg
Study NCT02071381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1030 75mg
Study NCT03618459 — intervention group
Intervention type: OTHER
Intervention: Phone questionnaire
Description: Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
Study NCT00994032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous injection of cement into the vertebral body
Description: percutaneous injection of cement into the vertebral body
Study NCT00994032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: standard antalgic medical treatment
Study NCT01774006 — intervention group
Intervention type: OTHER
Intervention: individual embryo culture or group culture
Description: Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
Study NCT02580890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
Study NCT02580890 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
Study NCT00543790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA-027
Description: PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
Study NCT04351191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Regular dose
Description: Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Study NCT04351191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Loading Dose
Description: Hydroxychloroquine administered as a loading dose only
Study NCT04351191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Study NCT04351191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of Care plus placebo